<DOC>
	<DOCNO>NCT00089115</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Vaccines make person 's cancer cell may make body build immune response kill cancer cell . Colony-stimulating factor GM-CSF increase number immune cell find bone marrow peripheral blood . It yet know whether combine rituximab GM-CSF vaccine therapy may cause strong immune response kill cancer cell . PURPOSE : This randomized phase III trial study give rituximab GM-CSF together vaccine therapy compare give rituximab GM-CSF alone treat patient newly diagnose , relapse , refractory B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Vaccine Therapy Sargramostim Compared With Placebo Sargramostim Following Rituximab Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare time disease progression patient grade 1 , 2 , 3 follicular B-cell non-Hodgkin 's lymphoma respond ( i.e. , complete partial response , stable disease ) treatment rituximab treat sargramostim ( GM-CSF ) v without autologous immunoglobulin idiotype-KLH conjugate vaccine . Secondary - Compare response rate improvement patient treat regimen . - Compare overall complete response rate patient treat regimen . - Compare duration response patient treat regimen . - Determine safety regimens patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord prior treatment ( yes v ) response rituximab study ( complete response [ CR ] partial response [ PR ] v stable disease [ SD ] ) . All patient receive rituximab IV weekly 4 week . Five week last dose rituximab , patient assess response . Patients progressive disease remove study undergo randomization . Patients CR , PR , SD randomize 1 2 treatment arm . - Arm I : Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine subcutaneously ( SC ) day 1 . Patients also receive sargramostim ( GM-CSF ) SC day 1-4 . - Arm II : Patients receive placebo SC day 1 . Patients also receive GM-CSF SC day 1-4 . In arm , treatment repeat monthly 6 month absence unacceptable toxicity clinically significant progressive disease . After first 6 month , patient CR , PR , SD may continue receive treatment ( per treatment arm ) every 2 month 1 year ( total 6 dos ) every 3 month thereafter absence disease progression . Patients follow every 3 month 2 year every 6 month disease progression . PROJECTED ACCRUAL : A total 342 evaluable patient ( 171 per treatment arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular Bcell nonHodgkin 's lymphoma ( NHL ) Grade 1 , 2 , 3 Meets 1 follow criterion treatment rituximab : Treatment naïve Relapsed refractory disease prior chemotherapy Relapsed prior document response ( i.e. , complete partial response ) rituximab least 6 month duration Tumor accessible biopsy OR exist biopsy material ( take within past 6 month ) suitable vaccine preparation Measurable evaluable disease tumor tissue procurement vaccine production No 2 prior treatment regimen NHL Single regimens include follow : Maintenance rituximab Rituximab administer weekly 8 course Cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) plus rituximab* NOTE : *CHOP follow rituximab time relapse consider 2 treatment regimens No history CNS lymphoma meningeal lymphomatosis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 ( unless relate bone marrow involvement lymphoma ) Hemoglobin ≥ 10g/dL Hepatic Not specify Renal Not specify Cardiovascular No congestive heart failure Pulmonary No compromise pulmonary function Immunologic HIV negative No prior allergic response GMCSF No active bacterial , viral , fungal infection Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychiatric disorder would preclude study participation No malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ cervix No serious nonmalignant disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics See Chemotherapy At least 4 week since prior immunotherapy No prior radiolabeled antilymphoma antibody ( e.g. , iodine I 131 tositumomab ibritumomab tiuxetan ) No prior autologous allogeneic stem cell transplantation No prior lymphomaspecific idiotype immunotherapy ( e.g. , Id vaccine ) No prior investigational vaccine immunotherapeutic containing keyhole limpet hemocyanin ( KLH ) Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy More 9 month since prior fludarabine More 2 year since prior chemotherapy/rituximab combination therapy ( e.g. , CHOP/rituximab cyclophosphamide , vincristine , prednisone [ CVP ] /rituximab ) No 6 total prior treatment course fludarabine Endocrine therapy No concurrent steroid allergic reaction sargramostim ( GMCSF ) Radiotherapy See Biologic therapy At least 4 week since prior radiotherapy Surgery Not specify Other At least 4 week since prior experimental therapy No concurrent systemic immunosuppressive therapy No concurrent antilymphoma therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>